||Recombinant Human VEGFB (Accession # AAA91463) Pro22-Arg188 was produced in E. coli-derived.
|Predicted N Terminal:
||Supplied as a 0.2 µm filtered solution in Acetonitrile and TFA.
||Measured by its binding ability in a functional ELISA.Immobilized rrNeuropilin-1/Fc Chimera at 4 µg/mL (100 µL/well) can bind rhVEGF-B167 with a linear range of 0.3 - 20 ng/mL.
||Recombinant Human VEGFB has a calculated MW of 19 kDa (monomer).
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).